Vivek Rudrapatna
Gastroenterology · San Francisco, CANPI 1255750741
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AbbVie at 44.7% of the total. Reporting peaked in 2022 at $2,663 and has fallen 94.9% since, to $135 in 2025.
Across 73 payments — averaging $83.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- GSK$208
- Novo Nordisk$129
- Boehringer Ingelheim$106
- Mylan Specialty L.p.$56
- plus $258 from 10 others
Across 21 payments — averaging $93,510 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$715K
- Amgen$476K
- Sanofi US Services Inc.$223K
- Alnylam Pharmaceuticals Inc.$219K
- Blueprint Medicines Corporation$201K
- Tanabe Pharma America, Inc.$111K
- plus $19K from 1 others
What the payments were for
- Consulting fees$2,61043%
- Travel & lodging$2,48641%
- Food & beverage$99216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $2,722 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,610 |
| GSK | 8 | $208 |
| Novo Nordisk | 6 | $129 |
| Boehringer Ingelheim | 5 | $106 |
| Mylan Specialty L.p. | 2 | $56 |
| Viiv Healthcare Company | 3 | $50 |
| Bayer | 2 | $47 |
| Lilly USA, LLC | 3 | $37 |
| Pfizer | 1 | $22 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Medtronic | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
How this compares
$6,089 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in San Francisco
- Kenneth BinmoellerSan Francisco$507K
- Uma MahadevanSan Francisco$325K
- Francis YaoSan Francisco$159K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.